European review for medical and pharmacological sciences最新文献

The article "Preclinical study of vitamin D deficiency in the pathogenesis of metabolic syndrome in rats" by S.K. Mahjoub, M.A.A. Sattar Ahmad, F.O. Kamel, M. Alseini, L.M. Khan published in Eur Rev Med Pharmacol Sci 2022; 26 (23): 9001-9014-DOI: 10.26355/eurrev_202212_30575-PMID: 36524519 has been retracted in accordance with the Publisher and the Editor in Chief. Following the publication of the above-mentioned article, concerns were raised by a whistleblower and on PubPeer regarding multiple concerns affecting the reliability of the reported data. The journal contacted the corresponding author on multiple occasions and formally requested clarification and access to the original raw data supporting the published results. Despite repeated attempts, no response or supporting documentation was received. In accordance with COPE guidance, the journal conducted an independent assessment of the published material. This evaluation identified major methodological and analytical deficiencies and confirmed the concerns raised. On the basis of the available information, the reliability of the findings could not be verified and the conclusions of the study cannot be confirmed. Therefore, the article is retracted. The authors have been informed of this decision and have not responded. This article has been retracted. The Publisher apologizes for any further inconvenience this may cause.

Objective: This retrospective cohort study aims to uncover the potential clinical effectiveness of a novel ophthalmic solution containing cross-linked carboxymethyl cellulose (CX-CMC) and silk proteins (SP) in dry eye disease, evaluating its efficacy in improving Tear Breakup Time (TBUT) and Ocular Surface Disease Index (OSDI) over a 3-months treatment and in absorbing ultraviolet (UV) and blue light and promoting wound healing.

Materials and methods: Two different populations were retrieved from the database; the first group consisted of 20 dry-eye patients who underwent a 3-month treatment with an ophthalmic solution containing CX-CMC and SP. The second group was composed of 10 dry-eye patients who did not want to use any eye lubricant or other treatment. The outcome measures, TBUT and OSDI, were analyzed before (T0) and after (T3) treatment. In addition, the ophthalmic solution was investigated for its capacity to absorb UV and blue light and to promote wound healing. Specifically, UV and blue absorbance were tested by means of a UV-VIS spectrophotometer, while the wound healing test was conducted using two distinct cell lines to assess the efficacy of the solution in facilitating cicatrization.

Results: The ophthalmic solution effectively restored tear film stability, as evidenced by the improved TBUT values and reduced dry eye disease symptoms evaluated through the OSDI score. Furthermore, it demonstrated absorption capabilities within the UV and blue wavelength range. In terms of wound recovery, the ophthalmic solution supported cell motility compared to untreated cells.

Conclusions: The ophthalmic solution containing CX-CMC and SP was effective in improving dry-eye signs and symptoms in patients and in absorbing UV and blue light. Furthermore, the ophthalmic solution promoted wound healing in vitro. Collectively, the results suggest that CX-CMC and SP eye drops could serve as a promising tool for treating dry eye disease of various origins.

Objective: The aim of the study was to report clinical outcomes of intravitreal dexamethasone (DEX) implant in patients with epiretinal membrane (ERM)-associated diabetic macular edema (DME) unresponsive to intravitreal ranibizumab (IVR).

Materials and methods: 11 eyes of type 2 diabetes patients >18 years old with ERM-associated DME unresponsive to ≥3 IVR injections were included. Patients with central macular thickness (CMT) >300 µm following a single dose DEX implant between January 2021 and December 2023, suggesting unresponsiveness or poor response, were retrospectively evaluated. A full ophthalmologic examination was performed pre- and first-to-sixth month post-therapy, including measuring best-corrected visual acuity (BCVA), intraocular pressure (IOP), and retinal ultra-structural parameters like CMT, central 1 mm retinal thickness (RT), and central macular volume (CMV).

Results: The mean age was 66.50±5.01 years. BCVA increased considerably in the first two months (p<0.050) compared to pre-therapy. Changes in CMT, RT, and CMV were statistically significant for ≥4 months for CMT, five months for RT, and six months for CMV (p<0.050). Increased BCVA coincided with retinal ultra-structural healing throughout the same period. Most patients had predominantly normal IOPs. Anti-glaucoma medication was initiated in just three patients where IOPs were >25 mmHg.

Conclusions: DEX implant could be a reliable and effective therapeutic alternative for ERM-associated DME resistant to anti-VEGFs, particularly during the first 3 months of treatment, when it appears to be most effective. A single DEX implant can produce a satisfactory and reasonably safe response, and the treatment can be repeated even after the implant's potency has gradually declined. Importantly, improved BCVA and retinal ultra-structure following DEX implant could lessen the need for ERM surgery and multiple intravitreal anti-VEGF injections. If ERM-associated DME persists despite multiple DEX implants, surgery should be considered.

Objective: In orthopedic day-hospital interventions like knee arthroscopy, the choice of the short-acting local anesthetic to be used for spinal anesthesia may significantly impact both recovery times and hospital-related costs.

Materials and methods: This prospective, two-arm cohort study included 70 adult patients undergoing an elective knee arthroscopy for meniscectomy who received either spinal chloroprocaine (40 mg, 1%) or prilocaine (40 mg, 2%). Cost analysis was performed using an activity-based costing approach, whereby resource utilization was multiplied by corresponding unit tariffs and summed across the following cost domains: operating room time, recovery room time, nurse care time, physician (anesthesiologist) care time, drug and device usage, and any unplanned overnight hospitalization. The primary outcome was the mean procedure cost per patient; secondary outcomes included perioperative time metrics and adverse events.

Results: Seventy subjects were recruited and assigned to one of the two groups, each consisting of 35 patients. The mean cost of the procedure per patient was €604.76 in the chloroprocaine group vs. €938.09 in the prilocaine group (difference = €333.33). Recovery room time and physician (anesthesiologist) care time were significantly shorter in the chloroprocaine group compared to the prilocaine group (45.63 vs. 104.00 minutes and 57.86 vs. 100.57 minutes, respectively, both p-values < 0.001). Urinary retention occurred in five patients in the prilocaine group, compared to none in the chloroprocaine group. One patient in the prilocaine group required overnight hospitalization.

Conclusions: The use of chloroprocaine for spinal anesthesia was associated with significantly shorter perioperative care times and lower hospital-related costs compared to prilocaine. Nonetheless, further high-quality, multicenter randomized controlled trials are needed to confirm the pharmacoeconomic advantages of using chloroprocaine for cost-effective spinal anesthesia.

Objective: The aim of the study was to assess the effectiveness of bone bioactive rinse in promoting early wound healing following simple tooth extraction in diabetic patients.

Materials and methods: A prospective comparative study was conducted at King Abdulaziz University Dental Hospital between March and May 2025. The study included 48 diabetic patients undergoing simple tooth extractions. Patients were assigned to either a test group (n=28) that used a bone bioactive rinse or a control group (n=20) that received no intervention. Healing was assessed on days 5 and 14 using a modified Early Healing Index (scale 1-5).

Results: A total of 48 diabetic patients (mean age: 51.25 ± 11.8 years) were enrolled into the bone bioactive rinse group (n=28) and the control group (n=20). While socket dimension measurements (width, height, area) were not significantly different between groups at either day 5 or 2 weeks post-extraction (p > 0.05), the clinical healing index showed a marked difference. On day 5, 96.4% of patients in the rinse group achieved a 'very good' healing score, compared to only 5% in the control group (p < 0.001). By week 2, 100% of the test group maintained high healing scores, vs. 20% in the control group (p < 0.001). No significant gender-related differences in healing outcomes were observed (p > 0.3).

Conclusions: Bone bioactive rinse significantly enhances early wound healing after tooth extraction in diabetic patients and may serve as a valuable adjunct in clinical practice.

The article "Treatment of lean PCOS teenagers: a follow-up comparison between Myo-Inositol and oral contraceptives" by L. Pkhaladze, M. Russo, V. Unfer, M. Nordio, S. Basciani, A. Khomasuridze published in Eur Rev Med Pharmacol Sci 2021; 25 (23): 7476-7485-DOI: 10.26355/eurrev_202112_27447-PMID: 34919250 has been retracted in accordance with the Publisher and the Editor in Chief. Following the publication of the above-mentioned article, concerns were raised by a whistleblower and on PubPeer regarding the methodological and statistical validity of the study. The journal initiated an investigation in accordance with its editorial policies and the Committee on Publication Ethics (COPE) guidelines. The authors were contacted and provided the raw data underlying the study and a reply to the concerns raised. However, the journal's investigation confirmed the presence of serious methodological issues regarding study design, randomization, and statistical analysis. As a result, the Editor in Chief concluded that the reliability of the findings could not be assured. Therefore, the article is retracted. The authors have been informed of this decision and disagree with this retraction. This article has been retracted. The Publisher apologizes for any inconvenience this may cause.

Following the publication of a previous Expression of Concern, the article "Clinical significance of serum hepcidin-25 levels in predicting invasive fungal disease in patients after transplantation" by Chen J, Zhong L published in Eur Rev Med Pharmacol Sci 2013; 17 (13): 1769-1773-PMID: 23852902 has been retracted in accordance with the Publisher and the Editor in Chief. The Expression of Concern was issued to alert readers to a potential ethical breach arising from the transplantation procedures described in the article, in line with concerns raised in the literature on transplantation ethics. The authors were contacted on multiple occasions and were asked to provide a detailed response addressing the ethical concerns, as well as documentation demonstrating approval by an appropriate ethics committee and compliance with applicable ethical standards. No response or supporting documentation was received. In accordance with the journal's editorial policies and the Committee on Publication Ethics (COPE) guidelines, and in the absence of the requested information, the Journal has decided to retract the article. The authors did not respond to correspondence regarding this retraction. This manuscript has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/3998.

The Editor-in-Chief, in accordance with the Publisher, has retracted the following articles published between 2018 and 2020 on the grounds of figure duplication and manipulation, subsequent to concerns raised on PubPeer. The corresponding authors of all articles were asked to provide the original data, but no responses were received. This retraction notice pertains to the following articles and is carried out in accordance with the recommendations of the Committee on Publication Ethics (COPE): Liu SD, Meng WX, Xu L, Chi C, Sun X, Liu HY. GAS5 promotes myocardial apoptosis in myocardial ischemia-reperfusion injury via upregulating LAS1 expression. Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8447-8453. doi: 10.26355/eurrev_201812_16544. PMID: 30556886. Zhang HY, Li CH, Wang XC, Luo YQ, Cao XD, Chen JJ. MiR-199 inhibits EMT and invasion of hepatoma cells through inhibition of Snail expression. Eur Rev Med Pharmacol Sci. 2019 Sep;23(18):7884-7891. doi: 10.26355/eurrev_201909_18998. PMID: 31599450. Meng J, Liu GJ, Song JY, Chen L, Wang AH, Gao XX, Wang ZJ. Preliminary results indicate resveratrol affects proliferation and apoptosis of leukemia cells by regulating PTEN/PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 2019 May;23(10):4285-4292. doi: 10.26355/eurrev_201905_17933. PMID: 31173300. Shi S, Yi JL. S100A8/A9 promotes MMP-9 expression in the fibroblasts from cardiac rupture after myocardial infarction by inducing macrophages secreting TNFα. Eur Rev Med Pharmacol Sci. 2018 Jun;22(12):3925-3935. doi: 10.26355/eurrev_201806_15278. PMID: 29949169. Tan FZ, Dai HL. TAZ accelerates osteogenesis differentiation of mesenchymal stem cells via targeting PI3K/Akt. Eur Rev Med Pharmacol Sci. 2019 Aug;23(3 Suppl):81-88. doi: 10.26355/eurrev_201908_18633. PMID: 31389578. Yang RS, Wang YH, Ding C, Su XH, Gong XB. MiR-146 regulates the repair and regeneration of intervertebral nucleus pulposus cells via Notch1 pathway. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4591-4598. doi: 10.26355/eurrev_201906_18036. PMID: 31210285. Sun HW, Yang GL, Wang SN, Zhang YJ, Ding JX, Zhang XN. MicroRNA-92a regulates the development of cutaneous malignant melanoma by mediating FOXP1. Eur Rev Med Pharmacol Sci. 2019 Oct;23(20):8991-8999. doi: 10.26355/eurrev_201910_19299. PMID: 31696487. Shao JH, Yuan S, Qian QR, Zhu J. MicroRNA-183-5p suppresses the malignant progression of osteosarcoma via binding to AKT. Eur Rev Med Pharmacol Sci. 2019 Oct;23(19):8203-8210. doi: 10.26355/eurrev_201910_19127. PMID: 31646550. He W, Qiao ZX, Ma B. Long noncoding RNA FAM201A mediates the metastasis of lung squamous cell cancer via regulating ABCE1 expression. Eur Rev Med Pharmacol Sci. 2019 Dec;23(23):10343-10353. doi: 10.26355/eurrev_201912_19672. PMID: 31841188. These articles have been retracted. The Publisher apologizes for any inconvenience this may cause.

Objective: The 60-item Constitution in Chinese Medicine Questionnaire (CCMQ), based on a traditional nine-constitution framework, has been widely used in China for health assessments. However, its length poses a practical barrier to its widespread clinical use. A previous study in Japan suggested that a five-constitution model was more optimal for the Japanese population and subsequently developed a simplified 18-item questionnaire. This study aimed to validate the structure of this five-constitution model and establish the standalone diagnostic accuracy of the 18-item questionnaire.

Materials and methods: This was a secondary analysis of a cross-sectional dataset comprising 851 healthy Japanese participants who completed the 60-item CCMQ. We first used hierarchical clustering (the NbClust package) on the 18-item data to determine the optimal number of clusters. We then used principal component analysis (PCA) to analyze the structure of the clusters. Finally, a decision-tree model was developed to classify participants based on the 18 items, and its performance was evaluated using 10-fold cross-validation.

Results: Clustering analysis of the 18-item data confirmed that five was the optimal number of clusters. PCA revealed that the five groups were clearly separated along a primary "health axis". The decision-tree model, using only 18 items, successfully classified participants into five constitution types (a structure validated on the 18-item data itself), with an overall accuracy of 81.6% and a balanced accuracy of 81.3%.

Conclusions: The 18-item simplified questionnaire is a valid and reliable instrument for constitutional assessment in Japan. This concise tool effectively retains the structural and predictive information of the original 60-item version, offering a practical solution for large-scale research and personalized health management in clinical settings.

Objective: Aluminum phosphide poisoning, a leading cause of pesticide-related deaths, has a 70-100% mortality rate and no specific antidote. Intravenous lipid emulsion showed promise in case reports, possibly by sequestering phosphine. This pilot study evaluated the efficacy of intravenous lipid emulsion in reducing mortality and improving outcomes in acute aluminum phosphide poisoning.

Materials and methods: This single-center, randomized, open-label trial enrolled 98 adults with confirmed aluminum phosphide poisoning. Patients received standard care plus intravenous lipid emulsion (20% emulsion, 250 ml bolus then 250 ml over 20 min) or normal saline placebo within 24 h. The primary outcome was all-cause mortality.

Results: Baseline characteristics were similar (N=98; 48 intravenous lipid emulsion, 50 control). Intravenous lipid emulsion group mortality [22.9% (11/48)] was significantly lower than control [62.0% (31/50); relative risk 0.493, 95% confidence interval 0.335-0.725; p<0.001]. Intravenous lipid emulsion led to greater lactate reduction (-2.3 vs. -0.6 mmol/l; p<0.013) and bicarbonate increase (7.0 vs. 2.0 mmol/l; p<0.013). Survival was higher with intravenous lipid emulsion in fresh celphos (71.4% vs. 0%; p<0.001) and shock (50% vs. 0%; p=0.001) subgroups.

Conclusions: In this pilot trial, intravenous lipid emulsion as an adjunct to standard care significantly reduced mortality and improved metabolic parameters in acute aluminum phosphide poisoning, particularly in high-risk subgroups.